Company intelligence / Profile preview

Tan Thanh Holdings

Ownership: Private
Development stage: Other

Overview

Tan Thanh Holdings is conducting advanced-stage clinical development and regulatory approval activities for Oravax's oral VLP COVID-19 vaccine, with exclusive ASEAN regional rights, likely targeting broad populations and improved logistics

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologic
Industry: Biotech

Partnerships

Oravax Medical (exclusive ASEAN vaccine rights)Oramed Pharmaceuticals (Oravax developer)

Beyond the preview

Go deeper on Tan Thanh Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tan Thanh Holdings.